Alliances pay off
Mechelen – Genomics and drug discovery services company Galapagos NV, has triggered another milestone payment in its alliance with Janssen Pharmaceutica NV in the field of rheumatoid arthritis, receiving a milestone payment of EUR1.5m. To date, Galapagos has earned more than EUR24m in payments from Janssen under the alliance. At the same time, the Mechelen-based company said it had received a a 1m milestone payment under its alliance with GlaxoSmithKline in the field of infectious disease. Since the initiation of the GSK deal at the end of 2007, Galapagos has received a total of a 6m from the pharma giant. “Galapagos continues to make progress across its strategic alliances, showing that our alliance model delivers strong growth in R&D revenues,” said CEO of Galapagos Onno van de Stolpe.